| Identification | Back Directory | [Name]
Memoquin | [CAS]
616885-87-1 | [Synonyms]
Memoquin
Memoquin 2,5-Bis[6-[ethyl-[(2-
methoxyphenyl)methyl]amino]hexylamino]cyclohexa-2,5-
diene-1,4-dione | [Molecular Formula]
C38H56N4O4 | [MOL File]
616885-87-1.mol | [Molecular Weight]
632.88 |
| Hazard Information | Back Directory | [Description]
Memoquin is a multi-target-directed ligand for treatment of Alzheimer's disease. | [Uses]
Memoquin is an anti-amyloid and anti-oxidant multi-target-directed ligand. Memoquin is an orally active inhibitor of BACE-1 and AChE with IC50 values of 108 and 1.55 nM, respectively. Memoquin is a cognitive enhancer that prevents the Aβ-induced neurotoxicity mediated by oxidative stress. Memoquin can be used for the research of Alzheimer’s disease (AD)[1][2]. | [in vivo]
Memoquin (7-15 mg/kg; oral administration, once) rescues memory deficits of scopolamine-induced amnesia models[1]. Memoquin (15 mg/kg; oral administration, once daily, for 2-6 days) fully rescues memory deficits of Aβ1-42-induced amnesia models with a 6 days treatment[1]. | Animal Model: | Mice with scopolamine-induced amnesia[1] | | Dosage: | 7, 10 and 15 mg/kg | | Administration: | Oral administration; 7, 10 and 15 mg/kg, once | | Result: | Reversed the scopolamine-induced memory deficits and verified by a T-maze test. Rescueed episodic memory impairment at a dose of 15 mg/kg.
|
| Animal Model: | Mice with Aβ- induced amnesia[1] | | Dosage: | 15 mg/kg | | Administration: | Oral administration; 15 mg/kg, daily for 2, 4, and 6 days before behavioral testing | | Result: | Weekly alleviated the insult induced by Aβ1-42 for 2-4 days treatment and fully rescued with a 6-day treatment.
|
| [IC 50]
hAChE: 1.55 nM (IC50); BACE1: 108 nM (IC50) | [References]
[1] Capurro V, et al. Pharmacological characterization of memoquin, a multi-target compound for the treatment of Alzheimer's disease. PLoS One. 2013;8(2):e56870. DOI:10.1371/journal.pone.0056870
[2] Cavalli A, et al. A small molecule targeting the multifactorial nature of Alzheimer's disease. Angew Chem Int Ed Engl. 2007;46(20):3689-92. DOI:10.1002/anie.200700256 |
|
|